Equities

Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.34
  • Today's Change-0.13 / -5.26%
  • Shares traded106.81k
  • 1 Year change-93.41%
  • Beta4.8026
Data delayed at least 15 minutes, as of May 10 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Intelligent Bio Solutions Inc. is a life sciences company. The Company is engaged in developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It operates through two segments, namely Commercially available Intelligent Fingerprinting Products (IFPG) and Development Stage Saliva Glucose Biosensor Platform (SGBP). Its product portfolio includes a portable drug screening system that works by analyzing fingerprint sweat using a one-time cartridge and portable handheld reader and also includes a development stage range of biosensor- based Point of Care diagnostic tests (POCT) that are developed in the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology. Its product candidate is the Saliva Glucose Biosensor (SGB), a POCT expected to substitute the finger pricking invasive blood glucose monitoring for diabetic patients. Its Biosensor Platform helps to detect multiple biological analytes.

  • Revenue in USD (TTM)2.46m
  • Net income in USD-13.40m
  • Incorporated2016
  • Employees17.00
  • Location
    Intelligent Bio Solutions Inc142 West 57Th St Fl11NEW YORK 10019United StatesUSA
  • Phone+1 (646) 233-6971
  • Fax+1 (302) 575-1642
  • Websitehttps://ibs.inc/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Virios Therapeutics Inc0.00-5.07m6.83m4.00---------0.2673-0.26730.00--------------------------------------56.76------
Hepion Pharmaceuticals Inc0.00-48.93m6.90m22.00--1.09-----12.41-12.410.001.510.00----0.00-124.91-61.43-150.17-68.82-----------4,784.140.00-------7.92------
Enveric Biosciences Inc0.00-17.46m6.90m7.00--1.25-----8.15-8.150.000.71420.00----0.00-144.99-104.94-207.98-156.88-------243.54----0.00------7.14------
Longeveron Inc709.00k-22.21m6.98m23.00--3.43--9.85-10.18-10.180.32620.42450.0359--4.3130,826.09-108.45-63.15-139.35-75.6831.1733.70-3,020.17-441.02----0.00---41.98-19.78-17.92--26.80--
AiXin Life International Inc4.09m-2.09m7.00m207.00------1.71-0.0836-0.08360.1636-0.07650.82685.4310.0219,757.49-42.27-16.93---34.5416.2548.13-51.12-36.960.1515------51.0058.0867.18--194.59--
Tenax Therapeutics Inc0.00-7.71m7.02m5.00--0.132-----33.51-33.510.0027.150.00----0.00-102.20-199.16-159.72-285.64-----------82.130.0583------30.21------
Shuttle Pharmaceuticals Holdings Inc0.00-6.59m7.02m8.00--1.66-----0.441-0.4410.000.25240.00----0.00-90.28---104.75-------------49.560.1527-------112.71------
Protext Mobility Inc750.00-2.21m7.03m4.00------9,377.30-0.4692-0.46920.00001-0.01020.0405-------9,400.97-1,587.94----86.67-530.19-232,392.00-17,498.830.0002-1.36-----93.98-63.0927.35------
Intelligent Bio Solutions Inc2.46m-13.40m7.29m17.00--0.0877--2.96-131.37-131.3720.9126.670.18312.419.09144,726.50-99.96-80.65-157.15-224.8420.90---545.95-948.540.3864--0.1602--187.51367.97-28.00------
Cadrenal Therapeutics Inc-100.00bn-100.00bn7.36m3.00------------------------------------------------------------
Sentient Brands Holdings Inc160.00-379.70k7.41m2.00------46,338.73-0.007-0.0070.00-0.03080.0006-0.0026--80.00-149.74-224.47----462.5041.35-237,312.50-27,393.230.0005-0.6995-----16.18---100.19------
Kazia Therapeutics Ltd (ADR)14.89k-13.51m7.54m12.00--0.8199--506.28-0.8194-0.81940.00080.34880.0007--73.97---63.98-46.35-82.39-54.75-----90,714.45-497.17----0.1297--979.43-28.3118.19------
NuCana PLC (ADR)0.00-34.60m7.59m25.00--0.4072-----411.24-411.240.008.820.00----0.00-64.21-41.01-102.19-48.07-----------77.430.0259------13.71---21.70--
Trevena Inc3.13m-40.29m7.62m23.00------2.44-3.16-3.160.2611-0.44290.073.69--135,869.60-90.25-55.93-110.38-66.3546.56---1,289.25-3,134.414.66-15.431.33--847.61-11.4324.93---24.67--
National Graphite Corp0.00-1.97m7.72m0.00---------0.0221-0.02210.00-0.01930.00-------11,014.44-212.13---6,295.18---------------------1,432.70------
Data as of May 10 2024. Currency figures normalised to Intelligent Bio Solutions Inc's reporting currency: US Dollar USD

Institutional shareholders

5.94%Per cent of shares held by top holders
HolderShares% Held
Heights Capital Management, Inc.as of 31 Mar 2024108.25k3.81%
The Vanguard Group, Inc.as of 31 Mar 202415.49k0.54%
Citadel Securities LLCas of 31 Dec 202313.03k0.46%
Renaissance Technologies LLCas of 31 Dec 202312.30k0.43%
Citigroup Global Markets, Inc. (Investment Management)as of 31 Mar 20247.96k0.28%
OMERS Administration Corp.as of 31 Dec 20233.54k0.13%
Two Sigma Investments LPas of 31 Dec 20232.84k0.10%
Two Sigma Securities LLCas of 31 Dec 20232.45k0.09%
Tower Research Capital LLCas of 31 Dec 20232.11k0.07%
Geode Capital Management LLCas of 31 Dec 20231.03k0.04%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.